Sanofi culls early infectious disease, blood disorder asset as it ramps up phase 3 for also-ran COVID vax

Sanofi has made a small trim to its pipeline today, though its near-term R&D focus remains on the 35,000-patient COVID vaccine test it started last quarter.

First up for the chop (PDF) is sutimlimab, a complement C1s inhibitor pulled in phase 1 for immune thrombocytopenic purpura, a blood disorder that causes a drop in the number of platelets in the blood, increasing the risk of internal bleeding and caused by immune reaction against the body's platelets.